Home > News > Latest > FDA approves first biosimilar for the treatment of certain breast and stomach cancers

FDA approves first biosimilar for the treatment of certain breast and stomach cancers

The U.S. Food and Drug Administration today approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+). Ogivri is the first biosimilar approved in the U.S. for the treatment of breast cancer or stomach cancer and the second biosimilar approved in the U.S. for the treatment of cancer.

Spotlight

Other News

Dom Nicastro | April 03, 2020

More Trending news

FDA approves first biosimilar for the treatment of certain breast and stomach cancers

Spotlight

Other News

Spotlight

Resources

Line Optimizer - digital guided workflows for optimized pharma production operations

Artificial Intelligence in Drug Manufacturing

Driving Down Drug Costs: How Real-Time Transparency in PBMs Can Make a Difference

Line Optimizer - digital guided workflows for optimized pharma production operations

Artificial Intelligence in Drug Manufacturing

Driving Down Drug Costs: How Real-Time Transparency in PBMs Can Make a Difference